BAFF CAR-T Cells (LMY-922) for Treatment of Refractory Hematologic Malignancies
NCT07679919
·
clinicaltrials.gov ↗
PHASE1
Phase
NOT_YET_RECRUITING
Status
27
Enrollment
INDUSTRY
Sponsor class
Conditions
Non-Hodgkin Lymphoma
Chronic Lymphocytic Leukemia
Hairy Cell Leukemia
Multiple Myeloma
Interventions
BIOLOGICAL:
LMY-922
Sponsor
Luminary Therapeutics